Evidence map›Paper›PMID 39905264›Full record

ArticleNature biotechnology2025

Implantation of engineered adipocytes suppresses tumor progression in cancer models.

Hai P Nguyen, Kelly An, Yusuke Ito, Bhushan N Kharbikar, Rory Sheng, Breanna Paredes, Elizabeth Murray, Kimberly Pham, Michael Bruck, Xujia Zhou and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Hai P NguyenDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Kelly AnDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Yusuke ItoDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-1521-5931
Bhushan N KharbikarDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-0394-0308
Rory ShengDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-9254-8836
Breanna ParedesDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Elizabeth MurrayDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0009-0000-6973-8829
Kimberly PhamDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Michael BruckDivision of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0009-0009-7695-8016
Xujia ZhouDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Cassandra BiellakDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Aki UshikiDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-0889-4577
Mai NobuharaDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Sarah L FongDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Daniel A BernardsDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-8176-1690
Filipa LynceDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6615-7076
Deborah A DillonDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Mark Jesus M MagbanuaDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-2113-3593
Laura A HuppertDivision of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Heinz HammerlindlDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Jace Anton KleinDepartment of Nutritional Sciences, University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0009-0007-6732-2572
Luis ValdiviezUniversity of California Davis West Coast Metabolomics Center, Davis, CA, USA.
Oliver FiehnUniversity of California Davis West Coast Metabolomics Center, Davis, CA, USA.ORCID http://orcid.org/0000-0002-6261-8928
Laura EssermanDepartment of Surgery, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-9202-4568
Tejal A DesaiDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Sook Wah YeeDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8121-8746
Jennifer M RosenbluthDivision of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Nadav AhituvDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA. nadav.ahituv@ucsf.edu.ORCID http://orcid.org/0000-0002-7434-8144

Funding

Project 4: Combined targeting of DNA repair and macrophage-mediated immunosuppression in BRCA1/2-associated breast cancerP50CA168504 · DANA-FARBER CANCER INST · 2025 to 2025
$2.6M
In vitro models as a window to learn how to change outcomes in women at high risk of developing breast cancerR01CA281361 · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2025 to 2025
$1.1M
Developing liquid biopsy tests for malignant effusions using artificial intelligence-assisted, morphology-based isolation of tumor cellsR01CA292019 · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2025 to 2025
$676k
Bioengineering adipocytes for cancer therapyR01CA283826 · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2025 to 2025
$643k
Development of functional genomic technologies in miceK99HG012576 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Aki Ushiki · 2023 to 2024
$228k
California Institute for Regenerative Medicine (CIRM) EDUC4-12812California Institute for Regenerative Medicine (CIRM) SFSU EDUC2-12693NCI NIH HHS P50 CA168504NCI NIH HHS R01 CA281361NCI NIH HHS R01 CA283826NCI NIH HHS R01 CA292019NHGRI NIH HHS K99 HG012576NIDDK NIH HHS R01 DK124769U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 1P50CA168504U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 1R01CA283826U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (NHGRI) 1K99HG012576U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) 1R01DK124769
6 · The paper itself

Abstract

Tumors exhibit an increased ability to obtain and metabolize nutrients. Here, we implant engineered adipocytes that outcompete tumors for nutrients and show that they can substantially reduce cancer progression, a technology termed adipose manipulation transplantation (AMT). Adipocytes engineered to use increased amounts of glucose and fatty acids by upregulating UCP1 were placed alongside cancer cells or xenografts, leading to significant cancer suppression. Transplanting modulated adipose organoids in pancreatic or breast cancer genetic mouse models suppressed their growth and decreased angiogenesis and hypoxia. Co-culturing patient-derived engineered adipocytes with tumor organoids from dissected human breast cancers significantly suppressed cancer progression and proliferation. In addition, cancer growth was impaired by inducing engineered adipose organoids to outcompete tumors using tetracycline or placing them in an integrated cell-scaffold delivery platform and implanting them next to the tumor. Finally, we show that upregulating UPP1 in adipose organoids can outcompete a uridine-dependent pancreatic ductal adenocarcinoma for uridine and suppress its growth, demonstrating the potential customization of AMT.

Indexed as

AdipocytesPancreatic NeoplasmsAnimalsCell Line, TumorCell ProliferationDisease Models, AnimalDisease ProgressionFemaleHumansMiceOrganoidsUncoupling Protein 1Uncoupling Protein 1

Identifiers

PMID39905264
PMCPMC12319119

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.